Page 24 - Labatt Brain Tumour Research Centre Annual Report 2022 to 2023

24
IMAGINE 2021-22
Publications
Chan TSY, Picard D, Hawkins CE, Lu M, Pfister S, Korshunov A, Roussel MF, Wechsler-Reya RJ, Henkin J, Bouffet E, Huang A. Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. Neuro- Oncology Advances. 2021 Feb 18;3(1).
Coltin H, Sundaresan L, Smith KS, Skowron P, Massimi L, Eberhart CG, Schreck KC, Gupta N, Weiss WA, Tirapelli D, Carlotti C, Li KKW, Ryzhova M, Golanov A, Zheludkova O, Absalyamova O, Okonechnikov K, Stichel D, von Deimling A, Giannini C, Raskin S, Van Meir EG, Chan JA, Fults D, Chambless LB, Kim SK, Vasiljevic A, Faure-Conter C, Vibhakar R, Jung S, Leary S, Mora J, McLendon RE, Pollack IF, Hauser P, Grajkowska WA, Rubin JB, van Veelen MC, French PJ, Kros JM, Liau LM, Pfister SM, Kool M, Kijima
N, Taylor MD, Packer RJ, Northcott PA, Korshunov A, Ramaswamy V. Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica. 2021 Nov;142(5):859-871.
Chung J, Maruvka YE, Sudhaman S, Kelly J, Haradhvala NJ, Bianchi V, Edwards M, Forster VJ, Nunes NM, Galati MA, Komosa M, Deshmukh S, Cabric V, Davidson S, Zatzman
M, Light N, Hayes R, Brunga L, Anderson ND, Ho B, Hodel KP, Siddaway R, Morrissy AS, Bowers DC, Larouche V, Bronsema A, Osborn M, Cole KA, Opocher E, Mason G, Thomas GA, George B, Ziegler DS, Lindhorst S, Vanan M, Yalon-Oren M, Reddy AT, Massimino M, Tomboc P, Van Damme A, Lossos A, Durno C, Aronson M, Morgenstern
DA, Bouffet E, Huang A, Taylor MD, Villani A, Malkin D, Hawkins CE, Pursell ZF, Shlien A, Kunkel TA, Getz G, Tabori U. DNA Polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells. Cancer Discovery. 2021 May;11(5):1176-1191.
Das A, Morgenstern D, Sudhaman S, Coblentz A, Chung J, Stone S, Alsafwani N, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira L, Constantini S, Dvir R, Yalon-Oren M, Campino G, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan M, Opocher E,
Mola R, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler D, George
B, Damme A, Hijiya N, Gass D, Mcgee R, Mordechai O, Bowers D, Laetsch T, Lossos A, Blumenthal D, Sarosiek T, Yen L, Knipstein J, Bendel A, Hoffmann L, Luna-Fineman
S, Zimmermann S, Scheers I, Nichols K, Zapotocky M, Hansford J, Maris J, Dirks P, Taylor MD, Kulkarni A, Shroff M, Tsang D, Villani A, Aronson M, Durno C, A Shlein, Malkin D, Getz G, Maruvka Y, Ohashi P, Hawkins C, Pugh T, Bouffet
E, Tabori U. Mutation and Microsatellite Burden Predict Response to PD-1 Inhibition in Children With Germline DNA Replication Repair Deficiency. Pediatric Blood & Cancer. 2021 Nov;68:S95-S96.
Durno C, Ercan AB, Bianchi V, Edwards M, Aronson M, Galati M, Atenafu EG, Abebe-Campino G, Al-Battashi A, Alharbi M, Azad VF, Baris HN, Basel D, Bedgood R, Bendel A, Ben-Shachar S, Blumenthal DT, Blundell M, Bornhorst
M, Bronsema A, Cairney E, Rhode S, Caspi S, Chamdin A, Chiaravalli S, Constantini S, Crooks B, Das A, Dvir R, Farah R, Foulkes WD, Frenkel Z, Gallinger B, Gardner S, Gass D, Ghalibafian M, Gilpin C, Goldberg Y, Goudie C, Hamid SA, Hampel H, Hansford JR, Harlos C, Hijiya N, Hsu S, Kamihara J, Kebudi R, Knipstein J, Koschmann C, Kratz C, Larouche V, Lassaletta A, Lindhorst S, Ling SC, Link MP, Loret De Mola R, Luiten R, Lurye M, Maciaszek JL, MagimairajanIssai V, Maher OM, Massimino M, McGee RB, Mushtaq N, Mason G, Newmark M, Nicholas G, Nichols KE, Nicolaides T, Opocher E, Osborn M, Oshrine B, Pearlman R, Pettee D, Rapp J, Rashid M, Reddy A, Reichman L, Remke M, Robbins G,
Roy S, Sabel M, Samuel D, Scheers I, Schneider KW, Sen S, Stearns D, Sumerauer D, Swallow C, Taylor L, Thomas
G, Toledano H, Tomboc P, Van Damme A, Winer I, Yalon M, Yen LY, Zapotocky M, Zelcer S, Ziegler DS, Zimmermann S, Hawkins C, Malkin D, Bouffet E, Villani A, Tabori U. Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology. 2021 Sep 1;39(25):2779-2790.
Erickson AW, Habbous S, Wright F, Lofters AK, Jerzak KJ, Das S. Assessing the association of targeted therapy and intracranial metastatic disease: a population-based retrospective cohort study. JAMA Oncology. 2021 Aug 1;7(8):1220-1224.
Erickson A, Habbous S, Hoey C, Jerzak K, Das S. Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. NPJ Breast Cancer. 2021:7(1):17.
Gaebe K, Li AY, Das S. Clinical biomarkers for early identification of patients with intracranial metastatic disease. Cancers (Basel). 2021 Nov 27;13(23):5973
Ghannad-Zadeh K, Das S. One-carbon metabolism associated vulnerabilities in glioblastoma: a review. Cancers (Basel). 2021 Jun 19;13(12):3067.
2021
Baroni L, Sundaresan L, Heled A, Coltin H, Pajtler KW, Lin T, Merchant TE, McLendon R, Faria C, Buntine M, White CL, Pfister SM, Gilbert MR, Armstrong TS, Bouffet E, Kumar S, Taylor MD, Aldape KD, Ellison DW, Gottardo NG, Kool M, Korshunov A, Hansford JR, Ramaswamy V. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology. 2021: 23(8):1360-1370.
Bunda S, Zuccato JA, Voisin MR, Wang JZ, Nassiri F, Patil V, Mansouri S, Zadeh G. Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors. International Journal of Molecular Sciences. 2021 Apr 27;22(9):4548.
Campbell BB, Galati MA, Stone SC, Riemenschneider AN, Edwards M, Sudhaman S, Siddaway R, Komosa M, Nunes NM, Nobre L, Morrissy AS, Zatzman M, Zapotocky M, Joksimovic L, Kalimuthu SN, Samuel D, Mason G, Bouffet E, Morgenstern DA, Aronson M, Durno C, Malkin D, Maris JM, Taylor MD, Shlien A, Pugh TJ, Ohashi PS, Hawkins CE, Tabori U. Mutations in the RAS/MAPK pathway drive replication repair deficient hypermutated tumors and confer sensitivity to MEK inhibition. Cancer Discovery. 2021 Jun;11(6):1454-1467.